Rhythm Therapeutics, Inc.

Rhythm Therapeutics, Inc. (RTI) technology is expected to significantly improve upon the current low success rate of current ablation strategies in treating atrial fibrillation (AF). The company is pursuing a proprietary utilization of gene therapy to target key mechanisms causing AF. This gene therapy will be delivered to the heart via a minimally invasive, IP-protected approach.